Literature DB >> 12641275

Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: new immunobiological and molecular insights on a long-standing etiopathogenic association.

Riccardo Dolcetti1, José Menezes.   

Abstract

Undifferentiated nasopharyngeal carcinoma (UCNT) is characterized by its unique epidemiologic, immunobiologic, virologic, and clinicopathologic features. Aside from environmental risk factors and possible genetic susceptibility, infection by the Epstein-Barr virus (EBV) constitutes a well-documented link for the development of UCNT. However, despite the fact that UCNT is the human tumor associated most consistently with EBV, the role played by this virus in the pathogenesis of UCNT is still largely speculative and is a matter of ongoing debate. The purpose of this article is to review recent advances, particularly at the immunovirological and molecular levels, linking EBV infection to UCNT, and to discuss those aspects that may be of relevance for a better diagnosis and/or prognosis of this tumor, as well as for development of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641275     DOI: 10.1016/s0065-230x(03)87191-9

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  6 in total

1.  [Zn(phen)(O,N,O)(H2O)] and [Zn(phen)(O,N)(H2O)] with O,N,O is 2,6-dipicolinate and N,O is L-threoninate: synthesis, characterization, and biomedical properties.

Authors:  Lee-Fang Chin; Siew-Ming Kong; Hoi-Ling Seng; Yee-Lian Tiong; Kian-Eang Neo; Mohd Jamil Maah; Alan Soo-Beng Khoo; Munirah Ahmad; Tzi-Sum Andy Hor; Hong-Boon Lee; Swee-Lan San; Soi-Moi Chye; Chew-Hee Ng
Journal:  J Biol Inorg Chem       Date:  2012-07-24       Impact factor: 3.358

2.  In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin.

Authors:  Catherine Pioche-Durieu; Cécile Keryer; Sylvie Souquère; Jacques Bosq; Wolfgang Faigle; Damarys Loew; Mitsuomi Hirashima; Nozomu Nishi; Jaap Middeldorp; Pierre Busson
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 3.  Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.

Authors:  Xueyi Zheng; Yuhua Huang; Kai Li; Rongzhen Luo; Muyan Cai; Jingping Yun
Journal:  Viruses       Date:  2022-05-10       Impact factor: 5.818

4.  High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.

Authors:  Laura Caggiari; Massimo Guidoboni; Emanuela Vaccher; Luigi Barzan; Giovanni Franchin; Annunziata Gloghini; Debora Martorelli; Paola Zancai; Maria Teresa Bortolin; Mario Mazzucato; Diego Serraino; Antonino Carbone; Paolo De Paoli; Riccardo Dolcetti
Journal:  Infect Agent Cancer       Date:  2007-03-01       Impact factor: 2.965

5.  Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma.

Authors:  Anussara Prayongrat; Chakkapong Chakkabat; Danita Kannarunimit; Pokrath Hansasuta; Chawalit Lertbutsayanukul
Journal:  J Radiat Res       Date:  2017-07-01       Impact factor: 2.724

Review 6.  The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation.

Authors:  Ai-Di Gu; Mu-Sheng Zeng; Chao-Nan Qian
Journal:  Int J Mol Sci       Date:  2012-10-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.